Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

AXL overexpression

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

AXL overexpression	Colorectal Cancer	AXL overexpression	Colorectal Cancer	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3
AXL overexpression	Clear Cell Renal Cell Carcinoma	AXL overexpression	Clear Cell Renal Cell Carcinoma	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3
AXL overexpression	Non Small Cell Lung Cancer	AXL overexpression	Non Small Cell Lung Cancer	osimertinib Resistant: C3 – Early Trials osimertinib Resistant : C3	osimertinib Resistant: C3 – Early Trials osimertinib Resistant : C3
AXL overexpression	Non Small Cell Lung Cancer	AXL overexpression	Non Small Cell Lung Cancer	afatinib Resistant: D – Preclinical afatinib Resistant : D	afatinib Resistant: D – Preclinical afatinib Resistant : D
AXL overexpression	Non Small Cell Lung Cancer	AXL overexpression	Non Small Cell Lung Cancer	ASP8273 Sensitive: D – Preclinical ASP8273 Sensitive : D	ASP8273 Sensitive: D – Preclinical ASP8273 Sensitive : D
AXL overexpression	Ovarian Cancer	AXL overexpression	Ovarian Cancer	VS-6766 + BGB324 Sensitive: D – Preclinical VS-6766 + BGB324 Sensitive : D	VS-6766 + BGB324 Sensitive: D – Preclinical VS-6766 + BGB324 Sensitive : D
AXL overexpression	Squamous Cell Carcinoma of Head and Neck	AXL overexpression	Squamous Cell Carcinoma of Head and Neck	cetuximab Resistant: D – Preclinical cetuximab Resistant : D	cetuximab Resistant: D – Preclinical cetuximab Resistant : D
AXL overexpression	Melanoma	AXL overexpression	Melanoma	BGB324 Sensitive: D – Preclinical BGB324 Sensitive : D	BGB324 Sensitive: D – Preclinical BGB324 Sensitive : D
AXL overexpression	Melanoma	AXL overexpression	Melanoma	vemurafenib + BGB324 Sensitive: D – Preclinical vemurafenib + BGB324 Sensitive : D	vemurafenib + BGB324 Sensitive: D – Preclinical vemurafenib + BGB324 Sensitive : D
AXL overexpression	Adenoid Cystic Carcinoma	AXL overexpression	Adenoid Cystic Carcinoma	ADCT-601 Sensitive: D – Preclinical ADCT-601 Sensitive : D	ADCT-601 Sensitive: D – Preclinical ADCT-601 Sensitive : D